Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes

@article{Gianni2007AnthracyclineCI,
  title={Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes},
  author={Luca Gianni and Emanuela Salvatorelli and Giorgio Minotti},
  journal={Cardiovascular Toxicology},
  year={2007},
  volume={7},
  pages={67-71}
}
Doxorubicin is known to cause cardiomyopathy and congestive heart failure (CHF) upon chronic administration. A major obstacle to doxorubicin-containing multiagent therapies pertains to the possible development of cardiomyopathy and CHF at lower than expected cumulative doses of doxorubicin. For example, the cardiac toxicity of doxorubicin is aggravated by the anti-HER2 antibody Trastuzumab or by the tubulin-active taxane paclitaxel; however, the mechanisms by which Trastuzumab and paclitaxel… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 48 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 33 REFERENCES

Do clinical and lab 0 100 200 300 400 500 600 Control + PTX + DCT V xa m K / m ) %( DOXOL EPIOL noita rof etibate m lhocl A Fig

  • E. A. Perez, V. J. Suman, E. Nancy, Davidson, N. E. . Exploratory analysis from NCCTG N9831
  • 2 Taxane stimulation of DOXOL but not EPIOL…
  • 2007

Similar Papers

Loading similar papers…